Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib

Código QR

Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib

Lorlatinib—a ROS1/ALK inhibitor—is currently undergoing clinical trials for the treatment of non-small cell lung cancers. Here the authors develop synthetic routes to11C- and 18F-labelled lorlatinib, with subsequent PET imaging showing good blood brain barrier permeability in non-human primates.

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomas Lee Collier, Marc D. Normandin, Nickeisha A. Stephenson, Eli Livni, Steven H. Liang, Dustin W. Wooten, Shadi A. Esfahani, Michael G. Stabin, Umar Mahmood, Jianqing Chen, Wei Wang, Kevin Maresca, Rikki N. Waterhouse, Georges El Fakhri, Paul Richardson, Neil Vasdev
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/c6a81b2a14fd4e259767853846c7c586
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Hayato Mizuta, et al.
Publicado: (2021)

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
por: Zhu VW, et al.
Publicado: (2020)

An LC-MS Approach to Quantitative Measurement of Ammonia Isotopologues
por: Jessica B. Spinelli, et al.
Publicado: (2017)

Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
por: Ana S. Guerreiro Stucklin, et al.
Publicado: (2019)

Quantification of lactate from various metabolic pathways and quantification issues of lactate isotopologues and isotopmers
por: Wei Zhang, et al.
Publicado: (2017)

Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade
por: Sebastian R. Nielsen, et al.
Publicado: (2021)

Efficient hydrogen isotopologues separation through a tunable potential barrier: The case of a C2N membrane
por: Yuanyuan Qu, et al.
Publicado: (2017)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng L, et al.
Publicado: (2018)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019)

Sensitivity analysis of flux determination in heart by H₂ ¹⁸O -provided labeling using a dynamic Isotopologue model of energy transfer pathways.
por: David W Schryer, et al.
Publicado: (2012)

Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition
por: Ashiq Masood, et al.
Publicado: (2021)

Targeted inhibition in tumors with ALK dependency
por: Kwak EL, et al.
Publicado: (2013)

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
por: Schrock AB, et al.
Publicado: (2020)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
por: Marianne Oulhen, et al.
Publicado: (2021)

ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
por: Sebastian Y. F. Michels, et al.
Publicado: (2017)

ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells
por: Anna M. Schläfli, et al.
Publicado: (2021)

Association of Alk1 and Endoglin Polymorphisms with Cardiovascular Damage
por: Mercedes Garzon-Martinez, et al.
Publicado: (2020)

TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations
por: Ouseph MM, et al.
Publicado: (2019)

Venous identity requires BMP signalling through ALK3
por: Alice Neal, et al.
Publicado: (2019)

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
por: Zhu VW, et al.
Publicado: (2018)

ALK rearranged non–small cell lung carcinoma with EML4-NTRK3 fusion as a possible mechanism of resistance to third-generation ALK inhibitors
por: Elena Corral de la Fuente, et al.
Publicado: (2021)

Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
por: Liang L, et al.
Publicado: (2021)

ALK is frequently phosphorylated in Merkel cell carcinoma and associates with longer survival.
por: Jenni Jaatinen, et al.
Publicado: (2021)

Novel AlkB dioxygenases--alternative models for in silico and in vivo studies.
por: Damian Mielecki, et al.
Publicado: (2012)

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
por: Joelle C. Boulos, et al.
Publicado: (2021)

Electrochemical Hydroxylation of C3–C12 n-Alkanes by Recombinant Alkane Hydroxylase (AlkB) and Rubredoxin-2 (AlkG) from Pseudomonas putida GPo1
por: Yi-Fang Tsai, et al.
Publicado: (2017)

Jaime Ros Bosch, economista*
por: José I. Casar
Publicado: (2019)

Magnolio Media Group
por: Livni,Pedro
Publicado: (2020)

ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability
por: Wenlong Li, et al.
Publicado: (2021)

NAIL-MS reveals the repair of 2-methylthiocytidine by AlkB in E. coli
por: Valentin F. Reichle, et al.
Publicado: (2019)

Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer
por: Anna M. Wulf, et al.
Publicado: (2021)

ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
por: Christabel Wilson, et al.
Publicado: (2017)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns MW, et al.
Publicado: (2015)

ROS-Based Nanoparticles for Atherosclerosis Treatment
por: Xin Hu, et al.
Publicado: (2021)

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
por: Hayato Ogura, et al.
Publicado: (2017)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero Estela, et al.
Publicado: (2020)

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
por: Huan Zhang, et al.
Publicado: (2021)

First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi S, et al.
Publicado: (2015)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
por: Joanna Szydzik, et al.
Publicado: (2021)